Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Issues in antiplatelet therapy for UA/NSTEMI
Autore:
Chatterjee, K; Col, J; Dalby, AJ; Gulba, D;
Indirizzi:
UCSF, Moffit Long Hosp, San Francisco, CA 94110 USA UCSF San Francisco CAUSA 94110 it Long Hosp, San Francisco, CA 94110 USA Clin Univ St Luc, B-1200 Brussels, Belgium Clin Univ St Luc Brussels Belgium B-1200 t Luc, B-1200 Brussels, Belgium Milpark Hosp, Johannesburg, South Africa Milpark Hosp Johannesburg SouthAfrica Hosp, Johannesburg, South Africa Franz Volhard Klin, Berlin, Germany Franz Volhard Klin Berlin GermanyFranz Volhard Klin, Berlin, Germany
Titolo Testata:
EUROPEAN HEART JOURNAL SUPPLEMENTS
fascicolo: J, volume: 3, anno: 2001,
pagine: J24 - J31
SICI:
1520-765X(200108)3:J<J24:IIATFU>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
ST-SEGMENT ELEVATION; ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; ACC/AHA GUIDELINES; UNSTABLE ANGINA; TASK-FORCE; MANAGEMENT; RECOMMENDATIONS; BENEFIT;
Keywords:
antiplatelet; Gp IIb/IIIa antagonist; acute coronary syndromes; unstable angina; guidelines;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
12
Recensione:
Indirizzi per estratti:
Indirizzo: Chatterjee, K UCSF, Moffit Long Hosp, San Francisco, CA 94110 USA UCSF San Francisco CA USA 94110 San Francisco, CA 94110 USA
Citazione:
K. Chatterjee et al., "Issues in antiplatelet therapy for UA/NSTEMI", EUR H J SUP, 3(J), 2001, pp. J24-J31

Abstract

Options for antiplatelet therapy have increased in the last decade, with thienopyridines and GP IIb/IIIa receptor antagonists joining aspirin on the roster of available antiplatelet agents. Both North American (ACC/AHA) and European (ESC) cardiology societies have made recommendations regarding theuse of antiplatelet agents in recently issued practice guidelines for the management of acute coronary syndromes without ST-segment elevation. In September 2000, a group of international cardiologists meeting under the auspices of the International Cardiology Forum participated in a workshop to examine the new antiplatelet recommendations. Workshop participants generally agreed that both sets of guidelines were satisfactory, however there were areas of disagreement. The most controversial topic was the role or GP IIb/IIIa antagonists. Given the evidence for efficacy of these agents for medical management, many participants felt that their use was overemphasized. There was strong support for the use of GP IIb/IIIa inhibitors in the setting or intervention, although cost is prohibitive in many Countries. In view ofreal-world limitations, guidelines for alternative management strategies are needed. (C) 2001 The European Society of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 22:49:37